Incretin mimetics are ideal candidate therapies for T2D as they exert their actions specifically during hyperglycaemic conditions and have the additional capacity to regulate body weight ( Since 2005, six incretin therapy drugs have been approved by the FDA (United States) and the MHRA (United Kingdom) for T2D treatment: Exenatide, Lixisenatide, Liraglutide, Dulaglutide, Semaglutide and Tirzepatide, all of which are administered daily or once weekly via subcutaneous injection
While the long-term opportunity remains substantial, pricing pressure, regulatory developments, and execution capabilities will play a key role in determining the winners
When glucose normalizes, insulin secretion falls, which helps reduce the risk of hypoglycemia
This can improve tissue health and possibly slow down aging
In the interaction with host intestinal tissues, the gut microbiota influences brain functions, and microbial dysbiosis has been implicated in brain disorders such as Alzheimers disease (AD) and neuropsychiatric conditions (Wang W
Hydrate: Drink plenty of fluids to prevent dehydration, which can worsen dizziness